专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明公开

EP1814988A2 COMPOUND WITH AFFINITY FOR THE CYTOTOXIC T LYMPHOCYTE-ASSOCIATED ANTIGEN (CTLA-4) 审中-公开
标题翻译：不具有用于细胞毒性T淋巴细胞相关抗原的亲和力结合（CTLA-4）
公开(公告)号：EP1814988A2
公开(公告)日：2007-08-08
申请号：EP05817585.2
申请日：2005-11-25
申请人： Pieris AG
发明人： MATSCHINER, Gabriele , HOHLBAUM, Andreas , SCHLEHUBER, Steffen , PÖHLCHEN, Martin , SKERRA, Arne
IPC分类号： C12N15/10
CPC分类号： C07K14/47
摘要： The present invention relates to a compound with affinity for the cytotoxic T lymphocyte - associated antigen (CTLA-4), wherein the compound exhibits a synergistic mode of action in that the compound: (a) increases T cell priming or T cell expansion or the generation of memory T cells by blocking of CTLA-4, and (b) enhances effector T cell activity in tumor tissue or lymphoid tissue by blocking of CTLA-4. The compound of the invention can be a protein, a small organic molecule, a peptide, or a nucleic acid. The invention also relates to amutein derived from a protein selected from the group consisting of human neutrophil gelatinase-associated lipocalin (hNGAL), rat α2-microglobulin-related protein (A2m) and mouse 24p3/uterocalin (24p3), said mutein having binding specificity for the cytotoxic T lymphocyte-associated antigen (CTLA-4), wherein said mutein: (a) comprises amino acid replacements at at least one of the sequence position corresponding to sequence positions 33 to 54, 66 to 83, 94 to 106, and 123 to 136 of hNGAL, and (b) binds human CTLA-4 with a KD of 50 nM or less.The invention also relates to a pharmaceutical composition comprising such a compound or mutein as well as to various pharmaceutical uses of such a compound or mutein, for example, for the prevention and/or treatment of cancer, an auto-immune disease or an infectious disease.

IPRDB

热门服务

关于我们

友情链接

联系方式